|
|
| Industrie Pharmaceutique > Etude de marché sectorielle |
| Serono: PharmaVitae Profile |
|
|
|
|
€ 4 845,00 |
Editeur
: |
Datamonitor |
Langue
: |
Anglais |
Date de publication : |
Octobre 2006 |
Taille du document : |
144 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
|
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
The Drug Delivery Outlook 2001
176 pages | Juillet 2001 |
In an environment where there is constant pressure to launch new products onto the market, the cost of investment in drug delivery compares very favourably with new drug discovery.
Subseque |
955,00 €
|
| |
| |
The Pharmaceutical industry in the 21st Century
150 pages | Octobre 1998 |
Does the 21st century herald the beginning of a genomics revolution? Which disease areas will provide the greatest growth potential and why? Which technologies have the greatest potential to max |
795,00 €
|
| |
| |
ePharmacies: Strategic Implications for the Healthcare Industry
230 pages | Mars 2000 |
Increasingly, the pharmaceutical sector is being influenced by the Internet.Are you in a position to:- Predict future shifts in drug prescribing and purchasing behavior?- Anticipate consolidation in b |
955,00 €
|
| |
| |
Pain Therapeutics: A Strategic Re-evaluation.
198 pages | Août 2000 |
Pain management, though not a life-threatening disease, will have its proper place in the future healthcare system because the disability and economic loss in addition to personal suffering caused |
955,00 €
|
| |
| |
Healthcare In Wales
50 pages | Mai 2000 |
The Welsh Presentation Includes:- The Structure Of The NHS In Wales- Revenue Expenditure On Health Services In Wales- Number Of Hospital Units - Number Of Available Inpatient Beds- Number Of Occupied |
327,00 €
|
| |
| |
OTC Digestive Remedies in Germany
15 pages | Juillet 2002 |
The German market for OTC digestive remedies totaled Euro 446.9 million (US$421.9 million) in 2001, an increase of nearly 1% on the previous year and they remain important with a 11% share of all self |
198,00 €
|
| |
| |
The CNS Outlook 2000
203 pages | Octobre 2000 |
The Central Nervous System (CNS) market has shown sustained growth in 1999 with the expansion continuing to be driven by several factors.A greater understanding of the neuropharmacological mechanisms |
955,00 €
|
| |
| |
Pharmaceutical Packaging Market
80 pages | Avril 2002 |
This report will enable you to:Analyse the size of the UK market for pharmaceutical packaging between 1997 and 2006, by type: - cartons - containers - labels and leaflets - blister & strip p |
1 479,00 €
|
| |
| |
Patient Power in the Pharmaceutical Industry: The shift towards more informed, more powerful consumers of drugs
119 pages | Juin 1999 |
The dramatic rise in patient power in recent years presents a new and challenging opportunity to pharmaceutical companies, healthcare providers and governments alike.
A great need exists for ph |
795,00 €
|
| |
| |
Bridging the Pharmaceutical Earnings gap: Key Strategies in the race for growth
173 pages | Mars 2000 |
The favorable climate of the pharmaceutical sector has changed radically over the past ten years.
Where once near unrestricted revenue expansion existed, external pressures now act in unison |
955,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| Serono: PharmaVitae Profile |
|
|
Introduction
This analysis examines the historical and forecast performance for Serono in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
*Benchmark Serono's performance against key rivals in the ethical pharmaceutical sector
*Analyze the potential of Serono's product portfolio, present and future, in view of Merck KGaA's recent acquisition of the company
*Learn how Serono will rely heavily on Rebif to drive growth over the forecast period, benefiting from the company's US co-promotion deal with Pfizer
|
|
Introduction
This analysis examines the historical and forecast performance for Serono in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
*Benchmark Serono's performance against key rivals in the ethical pharmaceutical sector
*Analyze the potential of Serono's product portfolio, present and future, in view of Merck KGaA's recent acquisition of the company
*Learn how Serono will rely heavily on Rebif to drive growth over the forecast period, benefiting from the company's US co-promotion deal with Pfizer
|
|
|
PPLSEN
|
|
|
|
|
